Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Digital repository of Slovenian research organisations
About
Search
Browse
Statistics
Contacts
Login
Show document
A+
|
A-
|
|
SLO
|
ENG
Title:
Novosti v sistemskem zdravljenju karcinoma želodca
Authors:
ID
Ocvirk, Janja
(Author)
Files:
PDF - Presentation file,
download
(157,57 KB)
MD5: 126B5E11F5C9F27A730A14E856F94106
PID:
20.500.12556/dirros/b0a0c622-72ed-4531-a01c-f8402efe5f29
Language:
Slovenian
Typology:
1.04 - Professional Article
Organization:
OI - Institute of Oncology
Abstract:
Veliko bolnikom s karcinomom želodca (KŽ) in gastroezofegealnega prehoda (GEP) se bolezen po resekciji ponovi. Ponovitve so lokalne ali z oddaljenimi zasevki ali pa gre za kombinacijo obojega. Adjuvantna kemoterapija lahko pri nekaterih vrstah solidnih tumorjev celotno preživetje podaljša predvsem z zmanjšanjem ostanka mikrozasevkov. Vloga adjuvantne kemoterapije pri teh karcinomih ni tako jasna, adjuvantna radiokemoterapija pa značilno podaljša čas brez bolezni in celotno preživetje. Perioperativno zdravljenje s kemoterapijo ECF značilno podaljša preživetje brez bolezni in v celoti. Standardno zdravljenje za bolnike z napredovalim KŽ in GEP je kemoterapija ECF ali njene izpeljanke EOF, ECX in EOX. Učinkovito je tudi zdravljenje s taksani v kombinaciji s 5-FU in cisplatinom (TCF). Z novimi kombinacijami citostatikov in z uvajanjem novih citostatikov se srednje preživetje bolnikov s KŽ in GEP podaljšuje. V zdravljenje metastatskega KŽ in GEP pa prihajajo tudi tarčna zdravila. Določanje biomarkerjev in uvajanje tarčnega zdravljenja v kombinaciji s kemoterapijo odpira novo ero bolniku prilagojenega zdravljenja, tudi pri bolnikih z napredovalim KŽ in GEP.
Publication status:
Published
Publication version:
Version of Record
Year of publishing:
2010
Number of pages:
str. 34-36
Numbering:
Letn. 14, št. 1
PID:
20.500.12556/DiRROS-8655
UDC:
616.33-006.6-085
ISSN on article:
1408-1741
URN:
URN:NBN:SI:doc-2AP4K3WP
COBISS.SI-ID:
968571
Copyright:
by Authors
Publication date in DiRROS:
31.08.2018
Views:
3060
Downloads:
647
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.
Record is a part of a journal
Title:
Onkologija
Shortened title:
Onkologija
Publisher:
Onkološki inštitut
ISSN:
1408-1741
COBISS.SI-ID:
65324032
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:
31.08.2018
Secondary language
Language:
English
Title:
Advances in Systemic Treatment of Stomach Cancer
Abstract:
In a great deal of patients operated on for gastric and gastroesophageal junction cancer, the disease is likely to recur as local recurrence, distant metastases or the combination of both. In the treatment of certain types of solid tumors, adjuvant chemotherapy can prolong the overall survival by reducing residual micrometastases. The effect of adjuvant chemotherapy in the treatment of gastric and gastroesophageal junction cancer is not very clear, whereas adjuvant radiochemotherapy significantly prolongs the relapse-free interval as well as the overall survival. Perioperative treatment with ECF-based chemotherapy also prolongs significantly the disease-free and overall survival. ECF-based chemotherapy and the analogue regimens, such as EOF, ECX and EOX, are considered to be the standard treatment for advanced gastric and gastroesophageal junction cancer. The treatment with taxanes applied in combination with 5-FU and cisplatin (TCF regimen) is also very efficient. New combinations of cytostatics and application of new cytostatics in the treatment of patients with gastric and gastroesophageal junction cancer have significantly improved the median survival of these patients. Recently, also target drugs are being introduced in the treatment of gastric and gastroesophageal junction cancer. With the measurement of biomarkers and application of target drugs, a new era in the patient-adjusted treatment is opening, also in the treatment of patients with advanced gastric and gastroesophageal junction cancer.
Archive
niGradiv
Back
